Lixisenatide and beinaglutide Lixisenatide and beinaglutide, including EX-BID as discussed earlier, are classified as short-acting GLP-1RAs based on pharmacokinetic characteristics such as clearance half-life and concentration-time distribution
As a general clinical principle: Retest HbA1c no sooner than three months after commencing B12 replacement therapy, and ideally once haematological recovery has been confirmed Confirm haematological recovery normalisation of MCV and haemoglobin before interpreting the repeat HbA1c as reliable Use interim glucose monitoring such as fasting plasma glucose, OGTT, or self-monitored blood glucose (SMBG) to assess glycaemic control during the treatment period
These drugs, widely used for weight loss, mimic a natural hormone in the body to help regulate appetite, slow digestion, and, for some people especially those living with type 2 diabetes lower blood glucose levels
It is not a substitute for professional medical consultation or treatment
and colleagues suggests